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Abstract
The aim of this research was to assess the quality of life in patients with stage III ovarian cancer during the treatment period, 
depending on the applied therapeutic approaches.
A comparative analysis of the results of treatment of 350 patients with adenocarcinoma of the ovaries of III-IV stage, which 
have undergone suboptimal or non-optimal cytomelective surgery, was conducted. To assess the quality of life and to examine the 
relationship between changes in physical health and quality of life, patients in both groups were asked to complete the questionnaires 
EORTC QLQ-C30 and SF-36. According to the questionnaire of the EORTC QLQ-C30, the indicators of physical activity, the ability 
to do everyday affairs, were higher in the second group of patients who received differentiated treatment. The indicator of “social 
functioning” was also higher in the II group of patients. When evaluating the patients’ liver on the scale of the questionnaire SF-36, 
it was found that the positive effect of differentiated therapy is maintained for 3 years. Life quality is an important criterion for eval-
uating the results of antitumor therapy, and when it is continuously monitored in patients with ovarian cancer the safety of treatment 
for patients could be improved, including at an advanced stage.
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1. Introduction
Over the past twenty years, the world’s scientific community has made a significant progress 
in the study of quality of life in patients with cancer. The increasing interest in this problem is due 
to revolutionary changes in the field of medical diagnostic technologies. The introduction of effec-
tive cytotoxication methods, the emergence of new chemotherapeutic agents, the widespread use of 
pharmacogenetic and pharmacogenomic approaches require a clinician to understand the basic laws 
of sanogenesis and the overall adaptation of the body at various stages of treatment of malignant neo-
plasms. The National Cancer Institute (NCI) recommends evaluating the effectiveness of treatment 
of oncopathology according to survival criteria and quality of life (QL) [1]. Evaluating quality of life 
not only helps in choosing a clinical decision but also avoids unwanted side effects. Data on QL in the 
dynamics after any medical intervention can improve the interaction of the patient and the physician, 
identify clinical priorities, including during the rehabilitation and palliative care.
The peculiarities of ovarian cancer (OC) evaluation in patients with ovarian cancer are due 
to several factors [2]. First of all, OC is an aggressive disease with a low survival rate and a high 
rate of relapse [3]. This disease is ranked first in terms of mortality among genital cancer in women 
with OC 46 % for all stages and 31 % for advanced stages [4]. Treatment of OC is based on radical 
surgical intervention and repeated courses of active chemotherapy. Stress, in which a woman lives 
Original Research Article:
full paper
(2017), «EUREKA: Health Sciences»
Number 5
38
Medicine and Dentistry
from the moment of diagnosis, is associated with uncertainty and anxiety, fear of death and a number 
of characteristic symptoms associated with the disease itself (weight loss, discomfort and abdominal 
pain, ascites, general exhaustion), or with side effects of therapy (changes in the skin, baldness, urinary 
and stools incontinence, swelling, loss of appetite and taste, insomnia, etc.) affect its ability to adapt to 
social life and self-reliance. Often, in patients with pancreatitis, manifestations of anxiety, depression, 
which also significantly affect QL, are defined, which is today considered as one of the most infor-
mative indicators characterizing the degree of human adaptability to living conditions and general 
state of health and allows determining the need for medical and psychosocial adaptation [5]. In recent 
years, the study of health related quality of life (HRQL) develops as a separate medical science with its 
own research methods, evaluation criteria, scope, etc. It is based on the definition by the World Health 
Organization (WHO) as an individual correlation of a position in the community’s life in the context 
of culture and society’s values system with the goals of an individual, plans, opportunities and degree 
of general disorder [6]. That is, the perception by a person of her position in life, including physical, 
mental and social wellbeing, regardless of the quality of the environment in which he lives, the degree 
of satisfaction with a particular level of life and other components of psychological comfort [7].
In a narrower sense, HRQL reflects, first and foremost, the impact of disease and applied 
medical technologies on general well-being of patients and satisfaction with treatment. At OC the 
main attention of researchers is paid first of all to the QL at the beginning of active treatment, as a 
criterion for the effectiveness of one or another method of treatment. At the stage of screening and 
early diagnosis, QL is studied less frequently, mainly in high-risk subpopulations (genetic burden, 
preventive salpingo-oophorectomy) [8].
2. Aim of research
To assess the quality of life of patients with stage III ovarian cancer during the treatment 
period, depending on the therapeutic approaches applied.
3. Material and methods
The study, realized on the base of oncology department of Odessa national medical univer-
sity (Odessa) during 2012–2016, conducted a comparative analysis of the results of treatment of 
350 patients with the ovarian adenocarcinoma of stage III–IV, who have undergone suboptimal or 
non-optimal cytoreductive surgery. Based on our approach and with the help of markers of resis-
tance to platinum preparations, all patients were divided into 2 groups.
In determining the probability of platinum refractoriness/platinum resistance, there was 
used the formula:
R 0,5 T 0,5 G 0,1 KA 0,3 NO + 0,1 UA,= × − × + × + × ×
where R is the risk of platinum resistance, with R>1.0 the resistance to platinum is probable, with 
R>1.0 the refraction to platinum is probable
T – compliance with the criteria formulated by Tyulyandin S. A. [2] (T (0–5);
G – presence of mutant alleles of BRCA1 5832insC and BRCA2 6174delAG polymorphisms 
in hetero- and homozygous variants (G (0–3);
KA – activity of catecholamines (KA (0–1);
NO – Expression of nitric oxide (NO (0–5);
UA – degree of hyperuricemia (UA (0–1);
At R<1.0 platinum resistance is unlikely, with R=1–1.5 the resistance to platinum is proba-
ble, and at R>1.5 the refraction to platinum is probable.
The first group (control group) – patients with serous OC (n=50) who received standard 
adjuvant first-line platinum chemotherapy without a developed concept of differential treatment 
(cisplatin 75 mg/m2 intravenous infusion of hydration and forced diuresis every 3 weeks);
Group II (main group) – 300 patients who, based on the criteria for detecting the sensitivity 
of ovarian cancer to chemotherapy with platinum preparations, were divided into 3 subgroups de-
pending on the predicted effect of platinum:
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1 subgroup (n=77) – patients with supposed platinum refraction, which treatment was start-
ed with chemotherapy of the second line (paclitaxel 175 mg/m2 intravenously every 3 weeks with 
standard premedication with corticosteroids, antihistamines and H2-histamine receptor blockers: 
12 mg of dexamethasone inside or intramuscular injection for 12 and 6 hours ranitidine 150 mg and 
50 mg dimedrol/m for 30–60 minutes before injection. Special infusion systems that do not contain 
PVC were used. In case of failure to purchase paclitaxel patients were administered by the scheme 
HemA (doxorubicin 50 mg/m2 intravenous infusion on day 1, gemcitabine 1000 mg/m2 intravenous 
infusion of 1, 8 day 21-day cycle PCT).
2 subgroup (n=98) – patients with predictable resistance to platinum OC for whom was 
realized the correction of disorders of sanogenesis and dysregulatory disease (nitric oxide donator, 
detoxicant, drugs that reduce uric acid levels in blood, hyperthermic chemophorfusion HYPEC) 
against the backdrop of a standard adjuvant chemotherapy by first-line platinum drugs.
3 subgroup (n=125) – the women with probably sensitive to platinum drugs OC, who have 
taken treatment with platinum according to standards (cisplatin 50 mg/m2 intravenous infusion of 
hydration and forced diuresis every 3 weeks).
To assess the QL and to study the relationship between changes in physical health and qual-
ity of life, patients in both groups were asked to complete the questionnaire EORTC QLQ-C30 [1]. 
Patients in the first and second groups filled the questionnaire EORTC QLQ-C30 simultaneously 
over the same period of time, corresponding to two courses of monochemotherapy.
The questionnaire EORTC QLQ-C30 includes 30 issues and consists of 5 functional scales: 
physical functioning (PF), role-functioning (RF), emotional functioning (EF), cognitive function-
ing (CF), social functioning (SF); 3 scales of symptoms: weakness (FA), nausea/vomiting (NV) 
and pain (PA); Overall Quality of Life Scale (QL); 6 single points: dyspnea (DY), sleep distur-
bance (SL), anorexia (AP), constipation (CO), diarrhea (DI), financial difficulties (FI). The high 
values of the functional scales reflect the high/healthy level of functioning, while the high values 
of the symptomatic scales indicate how many clinical symptoms of cancer are. For mathematical 
processing of the data, the Scoring manual EORTC manual was used.
All patients were additionally questioned using the Russian-language version of the SF-36 
questionnaire at the beginning of treatment and after the completion of treatment. The term of cat-
amnestic observation was 36 months.
The SF-36 questionnaire contains 36 points, of which 35 are used to process points in 
8 scales: physical functioning, role-playing, bodily pain, general health, viability, social function-
ing, emotional state, and mental health.
Quantitative assessment of the following indicators:
1. Physical Functioning (FF) (Physical Functioning – PF) reflects the degree of limitation of 
exercise physical activity including Self-service
2. Role Physical Functioning (RF) (Role-Physical Functioning – RP) – the influence of 
physical state on everyday roles activities (work, performance of daily duties).
3. Bodily Pain (BP) and its impact on the ability to engage in everyday activities, including 
work at home and abroad.
4. General Health (GH) – Assessing your current health status and prospects for treatment.
5. Vital (F) (Vitality – VT) – a subjective assessment by the respondent of her vitality (en-
ergy, vitality, and others.) Over the past four weeks, feeling full of strength and energy or vice 
versa – exhausted.
6. Social Activity (SA) (Social Functioning – SF) is characterized as a subjective assessment 
by respondents of the level of their relationships with friends, colleagues, relatives during the last 
four weeks.
7. Role Emotional Functioning (REF) (Role Emotional – RE) is a subjective assessment by 
the respondent of the degree of limitation of her daily activities, caused by emotional problems in 
the last four weeks.
8. Mental Health (MH) describes the mood, the presence of depression, anxiety and a gen-
eral indicator of positive emotions. Low rates indicate the presence of depressive, anxiety worries, 
mental illness.
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Scales are grouped into two general indicators of “physical component of health”, or “phys-
ical status” (FS) and “psychological component of health”, or “psychological status” (PS).
The determination of the probability of differences between the groups compared was per-
formed using the χ2 criterion, taking into account the Yates correction for pair comparisons and 
Bonferroni corrections for multiple comparisons with the control group. Statistical processing is 
performed using the software STATISTICA 10.0 (StatSoftInc., USA) [9].
5. Results
In assessing the quality of life of patients with RA on the background of different treatments 
there were identified the following changes, presented below in Table 1.
Table 1
Indicators of the questionnaire EORTC QLQ-C30
No. Subscales EORTC QLQ-C30 I group (n=50)
II group (n=300)
IIA (n=77) IIB (n=98) IIC (n=125)
1 General condition of health 40,3±1,6 41,5±1,9 43,8±1,4 45,5±1,3
2 Physical functioning 41,1±1,4 51,7±2,4 53,6±1,7 52,7±1,4
3 Role of functioning 44,4±1,9 53,3±3,2 51,6±2,5 51,1±1,9
4 Emotional functioning 66,0±2,1 69,5±3,0 70,7±2,4 71,7±1,8
5 Cognitive functioning 7,4±0,9 7,0±0,9 7,3±0,8 7,2±0,7
6 Social functioning 38,5±1,3 47,7±1,4 49,9±1,3 51,2±1,1
7 Fatigue 54,4±2,6 52,9±1,9 53,8±1,4 55,3±1,2
8 Nausea/Vomiting 36,3±0,3 12,2±1,4 8,8±0,7 6,9±0,3
9 Pain 57,7±3,3 73,6±2,8 74,4±2,1 75,5±1,8
10 Dyspnea 33,3±2,3 32,8±1,9 33,5±1,8 33,0±1,2
11 Insomnia 33,3±1,2 35,8±1,6 38,5±1,4 41,1±1,1
12 Loss of appetite 44,4±2,3 24,4±1,2 25,5±1,2 26,2±1,1
13 Constipation 38,9±2,7 33,3±2,2 31,6±1,6 29,8±1,3
14 Diarrhea 7,7±0,2 2,5±0,2 2,8±0,1 3,3±0,1
15 Financial difficulties 72,2±4,1 22,2±1,1 24,4±0,8 25,2±0,7
According to the questionnaire of the questionnaire EORTC QLQ-C30, the physical activity 
indicators, that is, the ability to do everyday affairs, were higher in the second group of patients 
who received differentiated treatment. The indicator of “social functioning” was also higher in the 
II group of patients. Subclass “Cognitive functioning”, which is responsible for concentration of at-
tention, interest in the environment, involvement in information technology, etc., in the evaluation 
gave results that were equally low in both group I and group II. Among symptomatic scales, a signif-
icant increase was found on the Pain scale in Group II (on average, 75.0±4.1), less pronounced – in 
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group I (57.7±3.3). According to the “Fatigue” scale, no significant differences were observed in 
both groups. Abnormalities in subscales “Nausea/Vomiting” and “Lower appetite” were twice as 
likely to be observed in group I. “Financial difficulties” in patients of group I were three times 
higher in comparison with group II. The importance of the final points of the questionnaire 
EORTC QLQ-C30 “General Health” and “Quality of Life” was higher in patients in group II.
When evaluating the patients’ liver on the scale of the questionnaire SF-36 it was established 
that the positive effect of differentiated therapy is maintained for three years (Fig. 1).
 
Fig. 1. Dynamics of indicators on the scale SF-36 
 Fig. 1. Dynamics of indicators on the scale SF-36
The most pronounced positive changes were observed in patients of the second group under 
subclasses of role-based physical functioning, pain, vitality and social functioning.
6. Discussion
The choice of tactics for patients with platinum-resistant ovarian cancer depends on 
assessing the functional reserves of the body. In addition to the criteria formulated by Tyuly-
andin S. A. [2], it includes the markers of the platinum-resistance prognosis parameters such as 
genetic encumbrance (absence of BRCA1 5832insC and BRCA2 6174delAG mutant alleles in 
the hetero- and homozygous variants), increased levels of catecholamines, high NO expression 
in situ, degree of hyperuricemia. In women with the presence of these factors, it is expedient 
to use medicinal correction of disorderly disturbances (nitric oxide donators, detoxicants, an-
ti-uremic drugs).
In the recently published systematic review [10] there was argued that despite the per-
sistence of psychological and physical symptoms, treatment sequelae, sexual problems, and fear of 
recurrence in some survivors, most studies demonstrated that OC survivors generally have good 
QOL compared to healthy women. Sereika S .M. et al. (2015) consider that better understanding of 
the different propensity for symptoms based on age as well as their life quality can help clinicians 
not only address them but also choose chemotherapies to minimize them [11]. Ledermann J. A. 
et al. found the positive effect of chemiotherapy on life quality of patients suffering from ovar-
ian cancer [12]. Phippen N. T. et al. (2017) evaluated the association between baseline quality of 
life and changes in QOL with progression-free disease and overall survival in advanced epithelial 
ovarian cancer [13]. OC relapse has a negative psychological and physical impact, highlighting the 
importance of time without recurrence and the need for effective treatment in the long term [14]. 
Quality of life predicts overall survival in women with platinum-resistant ovarian cancer as it was 
demonstrated in AURELIA substudy [15].
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Overall, women with advanced-stage ovarian cancer who have survived for at least 8.5 years 
report good QOL and psychological adjustment. QOL of survivors with multiple recurrences is 
somewhat impaired compared to those with low recurrence. Limitations include a possible bias 
towards participation by healthier survivors, thus under-representing the level of compromise in 
long-term survivors. Health care practitioners should be alert to psychosocial issues faced by these 
long-term survivors to provide interventions that enhance QOL [16]. Bhugwandass CS et al. (2016) 
assessed differences in health-related quality of life between patients with early-stage ovarian can-
cer who did or did not receive chemotherapy as adjuvant treatment. They found that patients who 
receive adjuvant chemotherapy have a significantly worse score for 3 aspects of HRQOL [17].
Thus, HRQOL is an important criterion for evaluating the results of antitumor therapy [18] 
and when it is constantly monitored in patients with OC, it is possible to increase the safety of treat-
ment for patients, including at an advanced stage [19]. However the current state of HRQOL use in 
the clinical practice in Ukraine requires improvement [20].
7. Conclusions
1. Differentiated treatment allows to improve the life quality in patients with OC during 
three years.
2. The use of a qualitative assessment of QL can be recommended as an additional criterion 
for the effectiveness of treatment of the serous OC.
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